Laboratoire XO moves into a new phase of its growth with the support of Stanley Capital

Press Release, october 04th, 2022 - Stanley Capital Partners (SCP) has acquired a majority stake in French pharmaceutical group Laboratoire XO (Lab XO). Debt was provided by US giant Ares Management.

Based in Saint Cloud, France, and founded in 2015, Laboratoire XO is specialized in the leveraging of mature MAs in various therapeutic areas such as pain, central nervous system, cardiology, oral care and women’s health. With sales of 60 million euros, 26 brands and a distribution network covering more than 45 countries (USA, Europe, Maghreb and French-speaking Africa), the Laboratoire XO team has demonstrated a strong ability to integrate mature big pharma brands and boost them to generate organic growth.

SCP will work actively with Laboratoire XO’s management to strengthen and develop the company through its next phase of growth. The acquisition of Laboratoire XO will serve as an investment platform for other planned acquisition projects. To date, Laboratoire XO has grown both organically, thanks to the international success of its brands, and externally through 18 acquisitions.

This investment brings SCP’s assets under management to $440 million.

A key step

The conclusion of this partnership with SCP and its team will be a key step in the further development of Laboratoire XO as a global player in the pharmaceutical industry. Having successfully developed the company in France and Europe, we are convinced that working with SCP will enable the team to reach its global potential and better serve our customers

Karine Pinon, CEO of Laboratoire XO

Simon Cottle, founding partner of SCP, said: “SCP is delighted to join forces with Karine Pinon and her excellent management team to accelerate Laboratoire XO’s growth with a global footprint. All parties share the vision of ambitious external growth with the lifecycle management expertise that characterizes Laboratoire XO.”

Patrick Hargutt, founding partner of SCP, said, “Using our proprietary research and AI sourcing technology, a few years ago we had identified Laboratoire XO as one of the major platforms in the commercial exploitation of mature products.”

About Stanley Capital Partners LLP

Stanley Capital Partners LLP (SCP) is a fast-growing, European-focused, middle-market capital investment firm that uses research and technology to identify investment opportunities to transform companies in the growth sectors of healthcare, technology and resource efficiency.

SCP targets companies with enterprise values of $250 million to $2.5 billion or more, where SCP can partner with management teams to create value through M&A, operational change and technology activation. SCP was founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt, has a team of 12 professionals. Laboratoire X.O represents the 4th investment SCP has led since its inception in 2019, demonstrating SCP’s strong ability to create investment opportunities and deploy capital. Today, SCP has assets under management of $440 million.